During the broadcast, Dr. Connie Lehman shared a five-year breast cancer risk estimate for NBC anchor Savannah Sellers, generated from her mammogram images by the CLAIRITY BREAST AI platform

Clairity, Inc., advancing AI-powered human health solutions, today announced a demonstration of its FDA-authorized CLAIRITY BREAST platform on NBC’s TODAY Show. The segment featured NBC anchor Savannah Sellers, who provided her mammogram images for analysis by the CLAIRITY BREAST AI platform for educational and informational purposes. Dr. Connie Lehman, Clairity’s founder, discussed the resulting five-year breast cancer risk estimate with Sellers during the broadcast.

During the broadcast, Dr. Lehman explained how CLAIRITY BREAST estimates a woman’s five-year breast cancer risk using a routine screening mammogram. The demonstration offered viewers a look at how AI can reveal new information from standard screening images to support more precise and equitable approaches to breast health.

“This moment captures what we’ve been working toward at Clairity, helping people understand their personal health risk so they can make more informed decisions about cancer care and prevention,” said Dr. Lehman. “Within the field of radiomics, advancements in AI are unlocking new insights from the data embedded in mammograms, allowing us to identify individuals with a higher risk of developing cancer. These insights can help clinicians tailor each patient’s care plan and adjust it over time as their health, lifestyle, and family history evolve.”

The TODAY Show feature follows Clairity’s U.S. Food and Drug Administration (FDA) De Novo authorization earlier this year for CLAIRITY BREAST, a novel, image-based prognostic platform designed to predict five-year breast cancer risk from a screening mammogram. Clairity is partnering with leading health systems across the country to expand access to its technology through 2025, advancing a new era of personalized breast screening and prevention.

“This TODAY Show segment marks a proud milestone for Clairity and raises awareness for women’s health,” said Jeff Luber, CEO of Clairity. “Our next phase focuses on integrating CLAIRITY BREAST into major healthcare systems. We’re thrilled to share that Beth Israel Deaconess Medical Center in Boston is the first medical center partner, demonstrating their leadership and commitment to innovation in women’s health. Additional health-system partnerships will be announced in the coming weeks and months as we continue expanding access nationwide.”

Clairity is launching CLAIRITY BREAST among leading health systems, ushering in a new standard for personalized, risk-based screening and cancer prevention. Women who wish to be notified when CLAIRITY BREAST becomes available through health systems in their area can join the waitlist at www.clairity.com.

Watch the TODAY Show segment HERE.

About CLAIRITY BREAST

The CLAIRITY BREAST software device is intended to generate a 5-year risk prediction of breast cancer based on a bilateral screening mammogram. CLAIRITY BREAST provides a prediction of the percentage probability that the individual will receive a diagnosis of breast cancer or develop breast cancer within the 5-year timeframe following the screening mammogram, through analysis of mammography features and characteristics. The AI model behind CLAIRITY BREAST was developed using 421,499 mammograms from 27 facilities across Europe, South America, and the U.S., and validated on more than 120,000 mammograms from ten geographically distinct U.S. screening centers, representing a diverse patient population. Validation was anchored in five-year outcome data. To learn more about its indications for use, visit: https://clairity.com/clairity-breast/

About Clairity

Founded in 2020 and headquartered in Boston, Massachusetts, Clairity, Inc. is transforming healthcare risk assessment through the power of artificial intelligence and deep learning. Backed by Santé Ventures, ACE Global Equity, and Breast Cancer Research Foundation, Clairity's platform can uncover subtle patterns in routine images that are invisible to the human eye, enhancing risk prediction to empower clinicians and their patients with actionable, personalized insights. Clairity’s mission is to shift the standard of care from late-stage treatment to proactive prevention across human health. To learn more, visit us at www.clairity.com | LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20251022786163/en/

“This moment captures what we’ve been working toward at Clairity, helping people understand their personal health risk so they can make more informed decisions about cancer care and prevention.”